Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABHD6 | Q9BV23 | 9/20 | 0.52 |
| ▸ | MGLL | Q99685 | 11/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | AXL | P30530 | 1/20 | 0.33 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.33 |
| ▸ | MERTK | Q12866 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27144253 | 1.00 | ABHD6 (0.52) | ABHD6MGLLHDAC4GPR119FAAH | |
| SCHEMBL30012054 | 0.90 | MGLL (0.52) | ABHD6MGLLAXLTYRO3MERTK | |
| SCHEMBL27149157 | 0.90 | MGLL (0.52) | ABHD6MGLLAXLTYRO3MERTK | |
| SCHEMBL27142614 | 0.89 | MGLL (0.55) | ABHD6MGLL | |
| SCHEMBL30012418 | 0.89 | MGLL (0.55) | ABHD6MGLL | |
| SCHEMBL27147866 | 0.85 | MGLL (0.53) | ABHD6MGLLFAAH | |
| SCHEMBL27151067 | 0.84 | MGLL (0.52) | ABHD6MGLLFAAHGRIN1GRIN2B | |
| SCHEMBL27153086 | 0.83 | MGLL (0.58) | ABHD6MGLL | |
| SCHEMBL27143399 | 0.82 | MGLL (0.51) | ABHD6MGLLFAAHAXLTYRO3 | |
| SCHEMBL27140111 | 0.82 | MGLL (0.51) | ABHD6MGLLGRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4326714-A1 | HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-02-28 | — | — | EP | claimed |
| CN-117295726-A | Heterocyclic compounds | 豪夫迈·罗氏有限公司 | 2023-12-26 | — | — | CN | claimed |
| WO-2022223750-A1 | HETEROCYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2022-10-27 | — | — | WO | claimed |
| US-20240199587-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2024-06-20 | — | — | US | disclosed |
| CN-117295726-A | Heterocyclic compounds | 豪夫迈·罗氏有限公司 | 2023-12-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199587-A1 | HETEROCYCLIC COMPOUNDS | CYP1B1, CYP1A1, CYP4B1 | ABHD6 2296/4885MGLL 4524/4885HDAC4 1611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.